Results 301 to 310 of about 172,791 (358)

Treatment of Atopic Dermatitis and Psoriasis Vulgaris With Bupropion-SR: A Pilot Study

, 2002
Jack G. Modell
openalex   +1 more source

Management Strategies for Generalised Granuloma Annulare: A Systematic Review of Current and Emerging Therapies

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Generalised Granuloma Annulare (GGA) is a chronic inflammatory skin disorder with no standard treatment. Since the last review in 2013, new treatments and varied responses have highlighted the need for an updated synthesis to guide clinical decisions.
Luca Bettolini, Vincenzo Maione, Andrea Carugno, Giorgio Stabile, Antonio Podo Brunetti, Zeno Fratton, Enzo Errichetti, Nicola Zerbinati, Franco Rongioletti, Piergiacomo Calzavara‐Pinton, Mariateresa Rossi, Stefano Bighetti   +11 more
wiley   +1 more source

Underreporting of sleep variables in psoriasis clinical trials

JEADV Clinical Practice
Grace Xiong, Nicholas Hua, Ron Vender
doaj   +1 more source

Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system

Andrology, EarlyView.
Abstract Background Growing evidence indicates that paternal condition significantly influences pregnancy outcomes and offspring health. However, assessing the safety of paternal drug exposure via randomized controlled trials poses ethical challenges, and relevant clinical studies consume a lot of resources to evaluate only a few drugs.
Yanbin Zeng, Wanlong Lin, Wei Zhuang
wiley   +1 more source

Evaluation of the treatment effectiveness of oral and intralesional steroids in idiopathic granulomatous mastitis using superb microvascular imaging

ANZ Journal of Surgery, EarlyView.
Abstract Objectives The objective of this study was to compare the efficacy of oral and intralesional steroid injection in the treatment of idiopathic granulomatous mastitis (IGM) cases with clinical, ultrasonography (US) and Superb microvascular imaging (SMI) findings.
Oğuz Karakayalı, Yasemin Kayadibi, Berrin Papila, Seda Aladag Kurt, Gökçen Yıldız Civan, Mehmet Velidedeoglu, Mehmet Halit Yılmaz   +6 more
wiley   +1 more source

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide

Alimentary Pharmacology &Therapeutics, EarlyView.
Most therapies used in inflammatory bowel disease appear safe and effective when used in chronic kidney disease including on renal replacement therapy, particularly biologic therapies. Some caution should be considered when using conventional therapies and JAK inhibitors.
Lynna Chen, Ashish Srinivasan, Suet‐Wan Choy, Jeffrey Van, Habeeb Habeeb, Andrew Nguyen, Abhinav Vasudevan   +6 more
wiley   +1 more source

Meta‐Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
There is uncertainty about the relative efficacy of subcutaneous (SC) compared to intravenous (IV) infliximab in inflammatory bowel disease (IBD). In this network meta‐analysis, SC infliximab was associated with high efficacy rates in IBD use, with a suggestion of clinical benefit above the IV formulation.
John David Chetwood, Arteen Arzivian, Yvonne Tran, Sudarshan Paramsothy, Rupert W. Leong   +4 more
wiley   +1 more source

Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk

British Journal of Haematology, EarlyView.
Inherited thrombocytopenia (IT) caused by germline variants in RUNX1, ETV6 or ANKRD26 carries a high risk of developing haematological malignancy. This study examined the clinical, platelet and molecular characteristics of 66 patients with these conditions, who carried 24 distinct genetic variants in the corresponding genes.
Ana Marín‐Quílez, Ana Sánchez‐Fuentes, Ana Zamora‐Cánovas, Pedro Luis Gómez‐González, Lorena Diaz‐Ajenjo, Rocío Benito, Agustín Rodríguez‐Alén, Teresa Sevivas, Thais Murciano, Laura Murillo, Nora V. Butta, Nuria Revilla, Rosa Campos, Paola Escribano, Jordi Esteve, Nuria Fernández‐Mosteirin, Francisca Ferrer‐Marín, Laura Hernández, Jorge Huerta‐Aragonés, Antonio León, Mónica López‐Duarte, Eugenia López, Mónica Martín‐Salces, Meritxell Nomdedeu, Raquel Oña, Irene Peláez‐Pleguezuelos, Fernando Ramos, Elena Sebastián, Claudia Serrano, Cristina Sierra‐Aisa, Rosa Vidal‐Laso, José Ramón González‐Porras, María Luisa Lozano, José María Bastida, José Rivera   +34 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Lymphomatoid Papulosis Following Spesolimab Treatment for Generalised Pustular Psoriasis

Australasian Journal of Dermatology, EarlyView.
Mizuho Namba, Mika Matsumoto, Naoya Saito, Atsuko Kimura, Chihiro Sagara, Daiki Rokunohe, Eijiro Akasaka   +6 more
wiley   +1 more source